Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QX 005N

Next Previous
Drug Profile

QX 005N

Alternative Names: QX-005N; SNC005; SNCA 005

Latest Information Update: 28 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qyuns Therapeutics
  • Developer Hangzhou Zhongmei Huadong Pharmaceutical; Qyuns Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antihistamines; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis; Prurigo nodularis
  • Phase II Rhinosinusitis
  • Preclinical Chronic obstructive pulmonary disease; Urticaria
  • No development reported Asthma
  • Discontinued Allergic rhinitis

Most Recent Events

  • 28 Oct 2025 No recent reports of development identified for preclinical development in Asthma in China (Parenteral)
  • 07 Oct 2025 Phase-III clinical trials in Atopic dermatitis in China (SC) (Qyuns Therapeutics pipeline, October 2025)
  • 07 Oct 2025 Phase-III clinical trials in Prurigo nodularis in China (Parenteral) (Qyuns Therapeutics pipeline, October 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top